ASTH

Astrana Health, Inc.

7 filings tracked

healthcarehealthcare managementMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

bullishMay 8

Revenue grew 56% to $965.1 million, driven by the Prospect acquisition.

earnings beat

80%

bullishMay 8

Care Enablement segment revenue surged 122% with a 23% operating margin.

margin expansion

70%

bearishMay 8

Total debt increased to $1.04 billion to fund acquisitions, increasing interest expense.

debt restructure

60%

neutralMay 8

Management identified a material weakness in internal control over financial reporting.

regulatory action

40%

Filing History

10-QMay 8, 2026

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. Astrana has successfully scaled its footprint and revenue through aggressive M&A, but this growth has come at the cost of a significantly heavier debt load and increased operational complexity. The divergence between the explosive Adjusted EBITDA growth and the rising medical liabilities creates a tension between short-term reporting wins and long-term solvency risks. Ultimately, the investment thesis now hinges on the company's ability to execute the Prospect integration and maintain its leverage ratios. While the Care Enablement segment provides a promising path toward high-margin software-like scalability, the underlying risk remains tied to the volatility of medical costs and the concentration of payer contracts. Investors must weigh the ability to capture value-based care efficiencies against the risks of a highly leveraged balance sheet and unstable internal financial controls.